Legend Biotech First Quarter 2025 Earnings: EPS Misses Expectations

Simply Wall St · 05/15/2025 10:00

Legend Biotech (NASDAQ:LEGN) First Quarter 2025 Results

Key Financial Results

  • Revenue: US$195.1m (up 108% from 1Q 2024).
  • Net loss: US$100.9m (loss widened by 69% from 1Q 2024).
  • US$0.55 loss per share (further deteriorated from US$0.33 loss in 1Q 2024).
earnings-and-revenue-growth
NasdaqGS:LEGN Earnings and Revenue Growth May 15th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Legend Biotech EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 112%.

Looking ahead, revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 12% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Legend Biotech's balance sheet.